Bio-Recherche — Omega 3 Cardio BT60

EPAX® is a brand of marine fish oil from EPAX Norway AS laboratories, recognized in the pharmaceutical and nutraceutical sectors for its high EPA+DHA concentration, analytical purity (controlled environmental contaminant levels), and stabilization against lipid oxidation. In a market where the quality of omega-3s varies considerably from one manufacturer to another—with oxidation indices (TOTOX, peroxide, anisidine) varying by tenfold depending on the source—the choice of a patented oil with documented analytical traceability is the primary selection criterion for this product. The dose of 336 mg EPA+DHA per capsule is consistent with the authorized EU 432/2012 claim, which requires a minimum of 250 mg/day of combined EPA and DHA. A single active ingredient, a single claim, a single documented mechanism—the formula is simple and honest in its positioning. The capsule is made of fish gelatin, not bovine or porcine gelatin—an advantage for individuals who avoid terrestrial animal products, but which excludes vegetarians and vegans, and requires a fish allergen declaration. Key pharmacist point: Regular daily doses of EPA fatty acids have antiplatelet properties. This mechanism is documented and constitutes a clinically significant interaction with anticoagulant and antiplatelet treatments—VKAs (warfarin, acenocoumarol), direct oral anticoagulants (rivaroxaban, apixaban, dabigatran), antiplatelet agents (aspirin, clopidogrel, ticagrelor). The manufacturer's warning ("not recommended for people with blood problems and those taking anticoagulant treatment") is pharmacologically correct. At 336 mg/day, the additional bleeding risk remains low in an untreated patient, but monitoring is justified in treated patients. Compatible with pregnancy at recommended doses: DHA is particularly important for fetal neurological development in the third trimester, and omega-3s at these doses are recommended by scientific nutrition societies.